ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

177
Analysis
Health CareChina
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
22 Aug 2019 11:21

Shanghai Henlius (复宏汉霖) IPO: Thoughts on Valuation

Shanghai Henlius, a subsidiary of Fosun Pharma, is seeking to list in Hong Kong. In our previous insights covering Shanghai Henlius, we have...

Logo
574 Views
Share
21 Aug 2019 02:46

Shanghai Henlius Biotech IPO Initiation: Going Large

Shanghai Henlius Biotech (1566213D HK) is a biopharmaceutical company and a non-wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group)...

Logo
657 Views
Share
17 Jul 2019 12:58

Shanghai Henlius (复宏汉霖) IPO: What's New in the Re-Filed Prospectus?

Shanghai Henlius, a subsidiary of Fosun Pharma, is seeking to list in Hong Kong. Shortly after its previous application lapsed, the company refiled...

Logo
708 Views
Share
06 Jul 2019 02:46

ECM Weekly (6 Jul 2019) - Budweiser APAC, Prime US REIT, Topsports, Douyu, JS Global, China Feihe

Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...

Share
03 Jun 2019 13:16

Shanghai Henlius (复宏汉霖) IPO: Valuation of Four Biosimilars

Shanghai Henlius, a clinical-stage pharmaceutical company back by Fosun Pharma, is seeking a listing in Hong Kong. In our previous insight, we have...

Logo
907 Views
Share
x